Silencing of PKM2 expression can contribute to radiosensitivity of non-small cell lung cancer (NSCLC)35, moreover, the combination treatment of cisplatin and RNA interference targeting PKM2 can significantly enhance the anti-tumor activity in A549 lung cancer xenograft model36. This evidence concerns the gene PKM and lung carcinoma.